Published in Cancer Weekly, August 4th, 2009
"Thalidomide was prescribed for its antiangiogenic properties. Bleeding settled within 1 week of starting 300 mg of thalidomide nocte. The effect appeared to be dose dependant, with bleeding recurring only when the dose was reduced to 100 mg of thalidomide nocte," wrote K. Lambert and colleagues.
The researchers concluded: "Palliative Medicine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-08-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.